Please ensure Javascript is enabled for purposes of website accessibility
Главная > Продукты > Антитела > Первичные Антитела
Цена(USD):
Спецификация:
  • 50ug
  • 100ug
  • 1mg
Количество:
Свяжитесь с нами
  • Обзор

  • Изображения

  • Ссылки

  • Даташит

  • SDS

Обзор
Каталожный номерAY257014
Описание
Anti-Obinutuzumab Polyclonal Antibody (AY257014) is a rabbit polyclonal antibody detecting Obinutuzumab in ELISA.
Highlights
  • ●Affinity Purified — Minimal background and high purity for reliable results.
Реактивность видовGeneral
ПримененияELISA
Хозяинский видRabbit
КлоональностьPolyclonal
ИзотипIgG
Иммуноген Obinutuzumab
Цель Rabbit polyclonal to Gazyva.
Специфичность The product is specific for Obinutuzumab. This antibody serves as an excellent positive control for Obinutuzumab immunogenicity (ADA) assays.
Уровень эндотоксинов Please contact with the lab for this information.
Чистота >90% as determined by SDS-PAGE.
Очистка Purified by antigen affinity column.
Номер доступа CAS: 949142-50-1
Форма Liquid
Буфер хранения 0.01M PBS pH 7.4

Пожалуйста, обратитесь к конкретной информации о буфере в печатной версии даташита или в индивидуальном сертификате качества (COA) для партии.

Информация об использовании продукта
Применение Разбавление
ELISA 1:5000-1:20000
IHC 1:50-1:500
WB 1:500-1:2000
Устойчивость и хранение Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
ФонObinutuzumab is a humanized anti-CD20 monoclonal antibody, originated by GlycArt Biotechnology AG and developed by Roche as a cancer treatment. It was approved under the trade name Gazyva by the US FDA in 2013, and as Gazyvaro by the EMA in Europe, for the treatment of chronic lymphocytic leukemia in combination with chemotherapy in treatment-naive patients, and as a second line treatment for follicular lymphoma. Obinutuzumab is a fully humanized monoclonal antibody that binds to an epitope on CD20 that partially overlaps with the epitope recognized by rituximab. Obinutuzumab binds to CD20 on B cells and causes these cells to be destroyed by engaging the adaptive immune system, directly activating intracellular apoptosis pathways, and activating the complement system.
Примечание For research use only.
Изображения
Ссылки
Formula
Mass (g) = Concentration (mol/L) × Volume (L) × MW (g/mol)
Enter any 2 of Mass, Concentration, Volume + Molecular Weight to solve for the unknown.
Mass
=
Concentration
×
Volume
Molecular Weight *
g/mol
Formula
C₁ × V₁ = C₂ × V₂
Enter any 3 of the 4 values to solve for the unknown.
Stock Solution
C₁ (Stock Conc.)
×
V₁ (Stock Vol.)
=
Working Solution
C₂ (Working Conc.)
×
V₂ (Working Vol.)
Рекомендация

Свяжитесь с нами для индивидуальных предложений, оптовых запросов и других вопросов.

Почта: [email protected]

Список дистрибьюторов